Compare
Immix Biopharma, Inc. vs Tenax Therapeutics, Inc. vs Celularity Inc vs Karyopharm Therapeutics Inc.
| Latest fiscal year | Immix Biopharma, Inc. IMMX | Tenax Therapeutics, Inc. TENX | Celularity Inc CELU | Karyopharm Therapeutics Inc. KPTI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $26.55M | $146.07M |
| Revenue growth (YoY) | n/a | n/a | -51.0% | +0.6% |
| Gross margin | n/a | n/a | 24.4% (computed) | n/a |
| Operating margin | n/a | n/a | -230.9% | -62.1% |
| Net margin | n/a | n/a | -345.4% | -134.2% |
| Net income | -$29.44M | -$52.60M | -$91.72M | -$196.04M |
| EPS (Diluted) | -$0.89 | -$1.34 | -$3.59 | -$17.93 |
| Operating cash flow | -$23.93M | -$35.80M | -$13.25M | -$75.37M |
| Free cash flow | -$24.66M | n/a | n/a | -$75.37M |
| Cash & equivalents | $93.93M | $97.60M | $6.17M | $60.54M |
| Total assets | $104.84M | $104.23M | $107.33M | $108.42M |
| Total liabilities | $11.04M | $7.16M | $145.39M | $401.34M |
| Shareholders' equity | $93.80M | $97.07M | -$38.06M | -$292.93M |
| Return on year-end equity | -31.4% | -54.2% | n/a | n/a |
| Shares outstanding | 52.95M | 9.31M | 28.84M | 18.31M |
Revenue, most recent five fiscal years
| Fiscal year | Immix Biopharma, Inc. | Tenax Therapeutics, Inc. | Celularity Inc | Karyopharm Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $26.55M Ended 2025-12-31 | $146.07M Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | $54.22M Ended 2024-12-31 | $145.24M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $22.77M Ended 2023-12-31 | $146.03M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $17.98M Ended 2022-12-31 | $157.07M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $21.34M Ended 2021-12-31 | $209.82M Ended 2021-12-31 |